Unione Europea -
italiano -
EMA (European Medicines Agency)
xalkori
pfizer europe ma eeig - crizotinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
xalkori 200 mg capsule rigide
pfizer ag - crizotinibum - capsule rigide - crizotinibum 200 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.84 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
xalkori 250 mg capsule rigide
pfizer ag - crizotinibum - capsule rigide - crizotinibum 250 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.05 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika